Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Rituxan(R) Plus FavId(TM) (Tumor-Specific Idiotype-KLH) and GM-CSF Immunotherapy in Patients With Grade 1 or 2 Follicular B-Cell Lymphoma

NCT00041730 is registered in ClinicalTrials.gov with Favrille as lead sponsor.

NCT NCT00041730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00041730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Rituxan(R) Plus FavId(TM) (Tumor-Specific Idiotype-KLH) and GM-CSF Immunotherapy in Patients With Grade 1 or 2 Follicular B-Cell Lymphoma
Lead sponsor
Favrille
Phase
Phase 2
Overall status
Unknown status
Start date
July 31, 2002
Completion date
Not reported
Enrollment
90
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma